Teresa Lozano

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

Live-Cell Microscopy for quantitative analysis of CAR T Cell fratricide and immune synapse.

Live-Cell Microscopy for quantitative analysis of CAR T Cell fratricide and immune synapse.

Journal: Methods in cell biology
Published: May 23, 2026

Analysis of murine CAR-T cell-mediated cytotoxicity in solid tumor models.

Analysis of murine CAR-T cell-mediated cytotoxicity in solid tumor models.

Journal: Methods in cell biology
Published: May 23, 2026

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

Journal: Blood
Published: March 02, 2026

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Journal: Molecular cancer
Published: September 08, 2025

Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myeloma.

Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myeloma.

Journal: Blood neoplasia
Published: August 19, 2025

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Journal: Blood
Published: July 21, 2025

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Journal: Blood
Published: July 21, 2025

Reprogramming CAR-T cells: Targeting SLC transporters for tumor microenvironment adaptation.

Reprogramming CAR-T cells: Targeting SLC transporters for tumor microenvironment adaptation.

Journal: Pharmacological research
Published: May 28, 2025

Targeting FOXP3 in glioblastoma: Blockade of tumor intrinsic effects boosts response to chemo-radiotherapy.

Targeting FOXP3 in glioblastoma: Blockade of tumor intrinsic effects boosts response to chemo-radiotherapy.

Journal: Life sciences
Published: April 11, 2025

Phosphatidylserine as a tumor target for CAR-T cell therapy.

Phosphatidylserine as a tumor target for CAR-T cell therapy.

Journal: Journal for immunotherapy of cancer
Published: February 03, 2025

Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma.

Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma.

Journal: Blood
Published: October 30, 2024

Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells.

Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells.

Journal: bioRxiv : the preprint server for biology
Published: September 24, 2024
Showing 1-12 of 52

Last Updated: 09/26/2026